Previous Close | 1.1200 |
Open | 1.1400 |
Bid | 1.1800 x 100 |
Ask | 1.2500 x 100 |
Day's Range | 1.1200 - 1.2392 |
52 Week Range | 0.8000 - 2.1000 |
Volume | |
Avg. Volume | 1,163,827 |
Market Cap | 137.908M |
Beta (5Y Monthly) | -0.10 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Conference Call and Webcast to be held May 14, 2024, at 10:00 a.m. Eastern TimeYARDLEY, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the first quarter 2024 and corporate updates, before market open, on Tuesday, May 14, 2024. Company to Host Conference CallMembers of the Company’s leadership team will host a conf
Led by Nantahala Capital and The D. E. Shaw Group with participation from existing and new investors Post-offering cash balance of ~$100 million expected to fund operating plan through 2025 Company expects XHANCE net revenues to be between $85 to $95 million for full year 2024 YARDLEY, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that it has entered into ag
Conference Call and Webcast to be held April 25, 2024, at 10:00 a.m. Eastern TimeYARDLEY, Pa., April 25, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced corporate updates detailing its commercial plans and expectations for XHANCE® (fluticasone propionate) following the recent FDA approval of a new indication for the treatment of chronic rhinosinusitis without nasal polyps